Price Action · 24 Months
From ¥1,617 in May 2024 the share climbed to ¥4,150 by August 2025 — a one-hundred-and-fifty-seven percent move on the FY25 price-revision windfall and the operating leverage that followed. Six months later it had handed back nearly all of it. The reasons sit in three disclosures: the December guidance reset, the February US-subsidiary impairment, and the Q1 print plus buyback announced after the close on May 14.
01 · THE RALLY The story of Cybozu's share price over the trailing two years is in two halves, separated by a single August 2025 peak. The first half is one of the cleanest operating-leverage prints any Japanese SaaS has produced: from ¥1,617 in May 2024 the stock climbed to ¥2,897 by year-end, paused briefly, and then resumed through the first half of 2025 to peak at ¥4,150 on August 19 — a one-hundred-and-fifty-seven percent move in fifteen months. The BoJ-driven flash low of ¥1,323 on August 5, 2024 was a single-day macro event, fully reversed within weeks. The substance behind the rally was visible across three sets of disclosures. FY24 full-year results, published in February 2025, showed revenue up 18.7% and operating income up 44.2%, with cloud share above eighty-eight percent. By the H1 FY25 print in August, the FY25 trajectory was unmistakable: management was on track to deliver revenue up 26.1% and operating income up +106% — an extreme operating-leverage year. Underneath those headline numbers sat one specific lever: the FY24/FY25 price revision combined with a minimum-user-count contract floor that lifted kintone ARPA from ¥30,900 to ¥47,100, a fifty-two percent step-up at the unit level. At the peak the stock implied roughly thirty times forward EV/EBIT — pricing FY25's print as if it were the new run-rate.
02 · THE REVERSAL The reversal began on December 17, 2025, when management published FY26 initial guidance: revenue up 12.7%, operating income up 4.1%. The OI growth rate had collapsed from +106% to +4%, and the implied forward multiple at the August peak no longer made arithmetic sense. The deceleration had two explanations — only one of which was intentional. The intentional half was reinvestment: FY26 plans embedded a cost-base step-up in advertising, R&D, and personnel (the latter including a special bonus tied to the FY28 ¥50.9bn revenue target). The unintentional half was structural: the FY25 ARPA jump was a one-time pricing event, not an annual lever. By mid-February 2026 a second disclosure compounded the first — the company recorded a ¥1,485M non-consolidated impairment on Kintone Corporation, the US subsidiary that has now accumulated eight years of losses (founded 2011), leaving the sub ¥355M underwater at FY25-end. Management explicitly retained the US thesis and signaled continued funding. The market discounted both the deceleration and the capital-allocation question, walking the stock down to a floor of ¥1,965 on April 13, 2026 — a fifty-three percent drawdown from the August peak.
03 · WHERE WE STAND NOW Two disclosures landed after the close on May 14, 2026. The Q1 FY26 tanshin printed revenue ¥10,246M (+17.0% YoY), operating income ¥3,014M (+15.3%), and net income ¥2,191M (+21.6%) — OI growth running fifteen points on revenue growth of seventeen at the new, higher absolute cost-base. That is the operating leverage of a SaaS engine at structural run-rate, distinct from the +106% windfall year. Q1 OP margin 29.4% sits four and a half points above the FY26 full-year guide of 24.9% — tracking ahead of the management plan. Same disclosure window, same day: a ¥3bn buyback for up to 3.0M shares (6.5% of outstanding), the first material repurchase since IPO. Combined with the FY26 DPS hike to ¥50 (up twenty-five percent), total FY26 capital return at the announced floor is approximately ¥5.3bn, or roughly seventy-one percent of forecast net income. The peak's multiple has not returned; the floor's multiple has been reset. What the next four quarters resolve is whether the price-revision lever is durable, whether the US subsidiary is investment or sunk cost, and whether the buyback is the start of a framework or a one-off.
04 · ALPHA vs BETA Over twenty-four months Cybozu returned +36% while TOPIX returned +44% — an eight-point relative shortfall. But the path is the point. Through August 2025 Cybozu had outpaced TOPIX by roughly one hundred and thirty points peak-to-peak; the entire drawdown handed back the alpha and then some. What was repriced is not the company — revenue keeps compounding at high-teens and operating income still levers above revenue — but the multiple investors are willing to pay before they see whether FY25 was a structural step-up or a one-time event. The May 14 disclosures begin to provide the answer.
Live Investor Debates
Three open debates currently visible in sell-side reports, IR Q&A, and price action. Each settles a different part of the multiple.
Capital-Efficiency Levers
Three disclosure or capital-policy levers visible in the filings. Each could reweight the multiple without requiring higher earnings.
Scenario Pathways
Three internally-consistent scenarios across the next four quarters. Each describes a different set of disclosure and operating outcomes — no single scenario is forecast; they are analytical bookends.
- FY26 OI lands at or below the ¥10.5bn guide — operating leverage does not re-establish.
- Second consecutive non-consolidated impairment of Kintone Corporation at FY26 results.
- Ehime arena commitment of ≥¥3bn announced without external financing or SaaS-pure carve-out.
- No ARPA decomposition disclosure; no second buyback or formal capital-return framework.
- Domestic kintone NRR slips below 115% as price-revision-driven seat expansion runs off.
The bear band of ¥1,500–¥1,800 implies ~5.8–7.0x FY26 forward EV/EBIT — below the JP private-buyer 7–10x range. Multiple-driven only if the market continues to discount the pricing-power durability beyond what a strategic buyer would.
- Q2 or Q3 FY26 guidance upgrade to full-year OI ≥¥11bn.
- kintone ARPA trajectory disclosed at mid-year or full-year results — separating durable lever from spent.
- ¥3bn buyback completes within the May 15 – Jul 31 window; capital-return framing at FY26 results acknowledges either a second authorization or a sustainable framework.
- No further Kintone Corp impairment; US revenue growth ≥30% YoY (first disclosure of the line itself is base case).
- ARPA decomposition disclosure: durable seat/tier lever shown to compound at high single-digits independent of further price action.
- Formal capital-allocation framework articulated — total-return floor of X% of NI annually with formula-based buyback gate.
- Kintone Corp committed-capital disclosure with a credible breakeven milestone (regardless of direction — disclosure is the catalyst).
- FY26 OI lands at ≥¥11.5bn (10% above guide), confirming leverage re-establishes at the higher cost-base.
- Ehime arena, if announced, routed via REIT or external sponsor structure with SaaS-pure equity carve-out.
The bull peak of ¥4,000 stays below the August 2025 high of ¥4,150 — the framework does not embed a return to the peak ~30x forward EV/EBIT multiple. That would require both ARPA re-acceleration AND the US/APAC business turning a structural corner, which is two-stage optionality outside this four-quarter scenario.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator (金融商品取引業者) under Japan's Financial Instruments and Exchange Act. JII does not have a 投資助言・代理業 registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion. JII does not have an investment opinion on any security discussed.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Conflicts & positions. JII may provide paid IR diagnostic, translation, or interpretation services to Japanese listed companies, including companies discussed in this publication. JII does not trade in or hold positions in the securities of companies profiled. Where a JII engagement exists with a profiled company, that fact will be disclosed at the top of the profile.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。